Figure 8

PPARα and γ regulate cubilin expression in PRTCs. A shows anti-cubilin and actin immunoblot analysis of detergent extracts of PRTCs treated with the PPARα agonist, Wy14643, at the indicated concentrations for 22 h. B shows densitometric analysis of three replicate anti-cubilin immunoblot experiments similar to A. C shows qPCR analysis of cubilin mRNA expression in PRTCs treated with the PPARα agonist, Wy14643, at the indicated concentrations for 22 h. D shows qPCR analysis of cubilin mRNA expression in PRTCs treated with either PPARα agonist (100 μM), PPARα antagonist, GW6471 (10 μM), or both for 22 h. E shows anti-cubilin and actin immunoblot analysis of detergent extracts of PRTCs treated daily with the PPARγ agonist, Rosiglitazone, at the indicated concentrations for 3 days. F shows densitometric analysis of three replicate anti-cubilin immunoblot experiments similar to E. G shows qPCR analysis of cubilin mRNA expression in PRTCs treated daily with the PPARγ agonist, Rosiglitazone, at the indicated concentrations for 3 days. H shows anti-cubilin and tubulin immunoblot analysis of detergent extracts of PRTCs treated twice with PPARγ antagonist, GW9662 (10 μM), PPARγ agonist, Rosiglitazone (25 nM), or both for 36 h. Asterisks indicate that differences between vehicle control and drug treatment groups were significant at p<0.05. Pound signs indicate that differences between agonist treatment alone and combined agonist with antagonist treatment groups were significant at p<0.05.